Last reviewed · How we verify
L-DEP
At a glance
| Generic name | L-DEP |
|---|---|
| Sponsor | Sun Yat-sen University |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Leucine for Depression Study (L-DEP) (EARLY_PHASE1)
- L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH (PHASE3)
- L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV-HLH (PHASE3)
- Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH (PHASE2)
- Trial to Incentivise Adherence for Diabetes (NA)
- L-DEP as an Initial Treatment for EBV-HLH (PHASE3)
- L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis (PHASE3)
- Epigenetic Effects of Diesel Exhaust and Ozone Exposure (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L-DEP CI brief — competitive landscape report
- L-DEP updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI